Revenue
2020
2021
2022
2023
2024
2025
Xeris Biopharma Holdings, Inc. (XERS)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $20.2M |
| Research & development | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M | $20.9M |
| Operating expenses | $266.9M | $236.7M | $207.9M | $192.2M | $164.7M | $104.0M |
| Operating income | $24.9M | −$33.6M | −$44.0M | −$81.9M | −$115.2M | −$83.5M |
| EBITDAderived | $26.2M | −$32.4M | −$42.5M | −$80.5M | −$113.8M | −$82.1M |
| Net income | $554,000 | −$54.8M | −$62.3M | −$94.7M | −$122.7M | −$91.1M |
| Basic EPSper diluted share | $0.00 | -$0.37 | -$0.45 | -$0.70 | -$1.55 | -$2.14 |
| Diluted EPSper diluted share | $0.00 | -$0.37 | -$0.45 | -$0.70 | -$1.55 | -$2.14 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 4, 2026Form 4 · 10b5-1 | HALKUFF DAWNDirector | SellCommon Stock | 20.0K | $6.09 | $121.8K | 95.0K |
| Jun 4, 2026Form 4 · 10b5-1 | BORMANN-KENNEDY BARBARA-JEAN ANNEDirector | SellCommon Stock | 16.0K | $6.09 | $97.4K | 126.5K |
| Jun 4, 2026Form 4 · 10b5-1 | JOHNSON JOHNDirector | SellCommon Stock | 15.0K | $6.09 | $91.3K | 683.1K |
| Jun 3, 2026Form 4 · 10b5-1 | PERSKY MARLADirector | SellCommon Stock | 15.5K | $5.90 | $91.5K | 126.5K |
| Jun 1, 2026Form 4 · 10b5-1 | Hecht BethSee Remarks | SellCommon Stock | 16.7K | $6.06 | $101.0K | 1.18M |